Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0BTXZB
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
aU2023308528A1 ADC3 (DAR of 8)
|
|||||
| Synonyms |
AU2023308528A1 ADC3 (DAR of 8)
Click to Show/Hide
|
|||||
| Organization |
PHEON THERAPEUTICS LTD
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
| Structure |
|
|||||
| Antibody Name |
huCDCP1 (F30-T667 Q525)-8xHis_T3
|
Antibody Info | Antigen Name |
Undisclosed
|
||
| Payload Name |
Exatecan
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
Mal-amido-PEG8-acid
|
Linker Info | ||||
| Conjugate Type |
Site-sepecific conjugation via photocrosslink and Click.
|
|||||
| Combination Type |
1- (3- (2,5-dioxo-2,5-dihydro-1h-pyrrol-1-yl)propanamido)-n- ((2s)-1- (( (2s)-1 (( (1s,9s)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,12,13,13a,14 octahydro-1h-benzo[de]pyrano[3',4':6,7]indeno[1,2-b]quinolin-1-yl)amino)-1 oxopropan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)-3,6,9,12,15,18,21,24 octaoxaheptacosan-27-amide
|
|||||
ADC-specific functional property(2027 Update)
Binding Affinity
| Dissocation Constant (Kd) | Binding Target | Description | Reference |
|---|---|---|---|
| 0.57 nM |
huCDCP1 (F30-T667Q525)-8xHisT3
|
In vitro pharmacology was assessed in binding experiments of unconjugated mAb and ADCs to recombinant target antigen ECD. The target antigen was huCDCP1 (F30-T667Q525)-8xHisT3.
|
[1]
|
Circulating Stability
| Incubation Time | 7day | Release | ≈25% | Reference |
[1]
|
|---|---|---|---|---|---|
| Incubation Medium | ADC3 was detected in mouse/human/cyno plasma after 7 days incubated with mouse/human/cyno plasma. | ||||
| Description |
ADC3 (DAR8) exhibited ~25% of linker-payload is lost after 7 days when incubated with mouse/human/cyno plasma. % DAR lost was calculated.
|
||||
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) | > 50% | Positive CALU-6 expression (CALU-6+++/++) | ||
| Method Description |
ADC3 (DAR of 8) was examined in a NSCLC CALU-6 (lung cancer) model after dosing at Q7dx3 at 3 mg/kg.
|
||||
| In Vivo Model | NSCLC CALU-6 (lung cancer) model | ||||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) | > 50% | Positive CALU-6 expression (CALU-6+++/++) | ||
| Method Description |
ADC3 (DAR of 8) was examined in a NSCLC CALU-6 (lung cancer) model after dosing at Q7dx3 at 6 mg/kg.
|
||||
| In Vivo Model | NSCLC CALU-6 (lung cancer) model | ||||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) | > 50% | Positive CALU-6 expression (CALU-6+++/++) | ||
| Method Description |
ADC3 (DAR of 8) was examined in a NSCLC CALU-6 (lung cancer) model after dosing at Q7dx3 at 10 mg/kg.
|
||||
| In Vivo Model | NSCLC CALU-6 (lung cancer) model | ||||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) | > 50% | |||
| Method Description |
ADC3 (DAR of 8) was examined in a NSCLC CALU-6 (lung cancer) model after dosing at Q7dx3 at 3 mg/kg.
|
||||
| In Vivo Model | MDA-MB-231 (TNBC) model | ||||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) | > 50% | |||
| Method Description |
ADC3 (DAR of 8) was examined in a NSCLC CALU-6 (lung cancer) model after dosing at Q7dx3 at 6 mg/kg.
|
||||
| In Vivo Model | MDA-MB-231 (TNBC) model | ||||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) | > 50% | |||
| Method Description |
ADC3 (DAR of 8) was examined in a NSCLC CALU-6 (lung cancer) model after dosing at Q7dx3 at 10 mg/kg.
|
||||
| In Vivo Model | MDA-MB-231 (TNBC) model | ||||